Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the co-lead programs target hepatocellular carcinoma and colorectal cancer) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.

He describes how Cloverleaf believes it is different from other tRNA companies and how it has already at the earliest stages benefitted...